Stocktoria
ELUTIA INC. ELUT
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-10-08
ELUTIA INC. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $12.3M | $14.5M | $24.7M | $23.8M | $47.4M | $42.7M | $42.9M |
| Gross profit | $6.6M | $6.7M | $11.1M | $11.6M | $19.0M | $20.6M | $19.8M |
| R&D expense | $4.2M | $3.0M | $4.4M | $7.7M | $9.3M | $6.0M | $2.4M |
| Operating income | -$26.9M | -$30.7M | -$30.5M | -$35.2M | -$23.0M | -$13.6M | -$8.4M |
| Interest expense | — | — | $5.8M | $5.1M | $5.3M | $5.6M | $5.4M |
| Income tax | $13,000 | $7,000 | $28,000 | $34,000 | $55,000 | $26,000 | $30,000 |
| Net income | $53.4M | -$53.9M | -$37.7M | -$32.9M | -$24.8M | -$21.8M | -$11.9M |
| EPS (diluted) | $0.87 | $-1.86 | $-2.07 | $-2.38 | $-2.38 | $-8.88 | — |
| Operating cash flow | -$44.8M | -$22.7M | -$21.8M | -$21.4M | -$15.4M | -$13.6M | -$7.2M |
| Free cash flow | -$46.7M | -$23.3M | -$22.1M | -$22.0M | -$15.8M | -$14.3M | -$7.8M |
| Cash & equivalents | $36.4M | $13.2M | $19.3M | $17.0M | $30.4M | $39.1M | $2.5M |
| Inventory | $2.6M | $1.9M | $3.9M | $4.2M | $9.6M | $10.1M | $7.2M |
| Total assets | $62.4M | $36.1M | $43.4M | $68.8M | $67.2M | $82.8M | $44.8M |
| Total liabilities | $34.7M | $82.4M | $82.0M | $73.9M | $53.6M | $62.0M | $55.4M |
| Shareholders' equity | $27.7M | -$46.3M | -$38.6M | -$5.0M | $13.5M | $20.8M | -$55.1M |
Growth · year-over-year · Revenue CAGR -18.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | -15.0% | -41.5% | +3.8% | -49.7% | +11.0% | -0.5% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.